Wang J, et al. - Researchers performed this meta-analysis to compare the safety as well as the efficacy of fulvestrant with aromatase inhibitors in postmenopausal women with hormone receptor-positive (estrogen and/or progesterone receptor positive) advanced breast cancer. For this investigation, they searched electronic databases for randomized controlled trials comparing the effectiveness and safety of fulvestrant with three aromatase inhibitors (anastrozole/letrozole/exemestane) published through August 31, 2017. Fulvestrant 500 mg displayed better efficacy than aromatase inhibitor, which was not seen with fulvestrant 250 mg in postmenopausal women with estrogen and/or progesterone receptor-positive advanced breast cancer. Fulvestrant prolonged time to progression/progression-free survival in the subgroups including estrogen and progesterone receptor-positive patients and those aged ≥ 65 years compared to aromatase inhibitors.